Integra LifeSciences Holdings Corporation is a medical technology company focused on the creation, production, and global distribution of advanced surgical implants and ...
Integra LifeSciences Holdings Corporation is a Princeton, New Jersey-based medical technology company founded in 1989. Its mission is centered on restoring patients' lives through products that support complex surgical procedures, tissue repair, wound management, and regeneration. The company operates primarily through two business areas: Codman Specialty Surgical and Tissue Technologies. ...Integra LifeSciences Holdings Corporation is a Princeton, New Jersey-based medical technology company founded in 1989. Its mission is centered on restoring patients' lives through products that support complex surgical procedures, tissue repair, wound management, and regeneration. The company operates primarily through two business areas: Codman Specialty Surgical and Tissue Technologies.
Codman Specialty Surgical provides products used in neurosurgery and neuro-critical care. Its portfolio includes systems for cerebral spinal fluid management, intracranial pressure monitoring, dural repair, tissue ablation, cranial stabilization, surgical visualization, lighting, and neurosurgical instrumentation. Integra also provides technical support, asset-management software, and aftermarket services connected with certain products. Its surgical instrument catalog includes approximately 40,000 designs and serves hospitals, surgery centers, dental practices, podiatric providers, veterinary practices, and other specialty users.
Tissue Technologies focuses on regenerative medicine and repair solutions. Products address acute and chronic wounds, skin and soft-tissue reconstruction, plastic and reconstructive surgery, hernia repair, bone grafting, peripheral nerve protection and regeneration, tendon reconstruction, and related orthopedic and general-surgery needs. These products can be particularly relevant when conventional closure or repair methods are insufficient, giving clinicians additional options for complex wounds and tissue defects.
The company's business model combines internally developed products, manufacturing capabilities, clinical and regulatory expertise, direct sales, distributors, and relationships with hospitals, integrated delivery networks, group purchasing organizations, and individual clinicians. Its bill of materials varies substantially by product category. Surgical instruments generally require precision metals, coatings, polymers, packaging, and sterilization processes, while regenerative products may involve specialized biological or engineered materials, membranes, scaffolds, or tissue-processing inputs. Manufacturing costs are therefore influenced by raw materials, quality systems, labor, sterilization, testing, regulatory compliance, distribution, and product-specific research and development.
Financially, the supplied information indicates approximately 4,427 full-time employees and revenue in the broad range of roughly $1.6 billion. The company has a diversified medical-device portfolio, but it also carries meaningful operating complexity, including inventory requirements, international distribution, research and development spending, regulatory obligations, and debt-related financial costs. The supplied trailing data show a gross margin of approximately 53.7%, research and development expense near 5.8% of revenue, and significant intangible assets, reflecting the importance of intellectual property, acquired technologies, brands, and regulatory approvals in the business. Integra does not currently report a regular dividend in the supplied data.
Stuart M. Essig is identified as chairman and chief executive officer. Key strategic priorities include continued product innovation, clinical adoption, portfolio expansion, manufacturing and supply-chain execution, quality and regulatory performance, and growth in neurosurgery and tissue reconstruction. The company distributes products throughout the United States, Europe, Asia-Pacific, and other international markets.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$1.6B
+1.5%
+6.8%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-516.5M
-7337.7%
+197.1%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
+51.7%
-5.6%
-8.3%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
+4.2%
+136.8%
-55.0%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
-31.6%
-7225.3%
+190.9%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-45.3M
-281.3%
+846.3%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
-2.8%
-278.5%
+798.4%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
194.8%
+51.7%
-0.8%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
2.54x
+116.8%
+0.7%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
Operator: Good day, and thank you for standing by. Welcome to the Integra LifeSciences Second Quarter 2026 Financial Results. At this time, all participants are in a listen-only mode. Please be advised that today's conference is being recorded. After the speakers' presentation, there will be a question-and-answer session. To ask a question, please press *1 on your telephone and wait for your name to be announced. To withdraw your question, please press *1 again. I would now like to hand the conference over to your speaker today, Christopher Ward, Senior Director of Investor Relations.
Christopher Ward: Good morning. And thank you for joining the Integra LifeSciences Second Quarter 2026 Earnings Conference Call. Joining me on the call are Stuart Essig, Chairman, President and Chief Executive Officer and Lea Daniels Knight, Chief Financial Officer. You should have the press release this morning announcing our second quarter 2026 financial results. We released an earnings presentation we referenced during the call is available at integralife.com under Investors, Events and Presentations, look for the file named second quarter 2026 earnings call presentation. Before we begin, I want to remind you that many statements made during the call may be considered forward-looking. Factors that could cause actual results to differ materially are discussed in the company's Exchange Act reports filed with the SEC. These factors are also detailed in the release. Also in our prepared remarks, we will reference reported and organic revenue growth. Organic revenue growth excludes the effects of foreign currency, acquisitions and divestitures. Unless otherwise stated, all disaggregated and franchise-level revenue growth rates are based on organic performance. Lastly, our comments today will include certain non-GAAP financial measures. Reconciliations of non-GAAP financial measures are included in today's press release, which is an exhibit to Integra's current report on Form 8-K filed today with the SEC. With that, I will now turn the call over to Stuart.
Stuart Essig: Thank you, Christopher. And good morning to everyone on the line. We are encouraged by our second quarter results. We delivered on our commitments, achieved important milestones, and advanced our key priorities across the business. As a result, we are operating with greater consistency and strengthening our foundation for long-term growth. Revenue for the second quarter was $419 million up $27 million sequentially and in line with our May guidance. Adjusted earnings per share were above the high end of our guidance range, driven by our improved operating execution, and favorable tariff dynamics in the quarter. We are reaffirming our full year organic revenue growth outlook and adjusted EPS guidance. As our underlying operating expectations for the year remain unchanged. We are updating our reported revenue outlook to reflect the impact of foreign exchange. Lea will provide additional color on our …
